Rallybio Corporation Profile Avatar - Palmy Investing

Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a…

Biotechnology
US, New Haven [HQ]

Risk Factors

By Management
Not Available

    No Risk Factor available yet. You can request "Risk Factors" through an email.

End of RLYB's Analysis
CIK: 1739410 CUSIP: 75120L100 ISIN: US75120L1008 LEI: - UEI: -
Secondary Listings
RLYB has no secondary listings inside our databases.